 |
|
 |
 |
|
||||||||||||||
|
Rimonabant Gain Green Signal For Sale in Brazil May 03, 2007 Counted as a major boost to the ever-growing popularity of rimonabant, a proven diet drug, ANVISA, the Brazilian health authority finally has privileged rimonabant, renowned extensively as Acomplia and Zimulti, with a right for sale in Brazil, the largest country of Latin America. As per the approval granted by the Brazilian health authority, Acomplia, a clinically tested preparation will be utilized as an add-on to exercise and diet plan while the treatment of obese patients having BMI above 30 and overweight people with BMI more than 27. In addition, the marvelous preparation also comes handy in the treatment of people with associated risk factors like type 2 diabetes and dyslipidemia. Thereby, now Brazil becomes a third country after the two large countries, Argentina and Mexico, where the diet drug have been generating waves and readily available in the market. Meanwhile, Netherlands gave a major setback to the repute of Acomplia by rejecting insurance reimbursement to patients buying the drug. And thus Netherlands becomes the latest European country who has serious issues with its existence and usage. |
||||||||||||||
